12/22
11:03 am
sngx
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
Low
Report
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
12/18
08:12 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
12/18
07:30 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
12/17
07:41 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
12/17
07:30 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
12/5
08:44 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad [Yahoo! Finance]
Medium
Report
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad [Yahoo! Finance]
12/5
08:30 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Low
Report
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
12/3
08:30 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Low
Report
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
11/19
08:05 am
sngx
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Medium
Report
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma [Yahoo! Finance]
11/19
07:30 am
sngx
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Low
Report
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
11/9
05:23 am
sngx
Soligenix GAAP EPS of -$0.58 beats by $0.05 [Seeking Alpha]
Low
Report
Soligenix GAAP EPS of -$0.58 beats by $0.05 [Seeking Alpha]
11/7
07:57 am
sngx
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results [Yahoo! Finance]
11/7
07:30 am
sngx
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Medium
Report
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
10/14
07:51 am
sngx
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Low
Report
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
10/14
07:30 am
sngx
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Medium
Report
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
10/7
07:30 am
sngx
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Medium
Report
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
9/30
07:55 am
sngx
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Low
Report
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
9/30
07:30 am
sngx
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Low
Report
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
9/29
04:05 pm
sngx
Soligenix Announces Closing of $7.5 Million Public Offering
Low
Report
Soligenix Announces Closing of $7.5 Million Public Offering
9/26
06:58 am
sngx
Soligenix Announces Pricing of $7.5 Million Public Offering [Yahoo! Finance]
Medium
Report
Soligenix Announces Pricing of $7.5 Million Public Offering [Yahoo! Finance]
9/26
06:33 am
sngx
Soligenix Announces Pricing of $7.5 Million Public Offering
High
Report
Soligenix Announces Pricing of $7.5 Million Public Offering